Insulin glargine (Basaglar)

Peptide

Also known as LY2963016

Approvedregulatory verdict

Evidence outlook

Approved: Type 2 Diabetes, Type 1 Diabetes

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (2)
CA
  • Adults with type 1 or type 2 diabetes (subsequent entry biologic to Lantus); pediatric type 1
Product first approved 2015pdf.hres.ca
EU
  • Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above
Product first approved 2014EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (5)
Type 1 Diabetes
NCT03338023 · Eli Lilly and Company
2018-03-23 – 2020-03-05 · Type 1 Diabetes
What this study did
Type 2 Diabetes
Phase 1 (7)
Type 1 Diabetes
NCT01600950 · Eli Lilly and Company
2012-05 – 2012-07 · Diabetes Mellitus, Type 1
What this study did
Other / comorbidity
NCT03555305 · Eli Lilly and Company
2018-09-26 – 2019-11-04 · Healthy
What this study did
NCT02955953 · Eli Lilly and Company
2016-11-14 – 2017-01-04 · Healthy
What this study did
NCT01688635 · Eli Lilly and Company
2012-09 – 2013-02 · Healthy
What this study did
NCT01634165 · Eli Lilly and Company
2012-07 – 2012-09 · Healthy Volunteers
What this study did
NCT01476345 · Eli Lilly and Company
2011-11 – 2012-07 · Diabetes Mellitus
What this study did
NCT01374178 · Eli Lilly and Company
2011-06 – 2011-07 · Diabetes Mellitus
What this study did
Phase 4 (4)
Type 1 Diabetes
NCT06717191 · Life for a Child Program, Diabetes Australia
2022-06-09 – 2024-08-02 · Type 1 Diabetes
What this study did
Type 2 Diabetes
NCT04864977 · Eli Lilly and Company
2021-08-16 – 2022-06-06 · Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
What this study did
NCT04153981 · Eli Lilly and Company
2019-12-16 – 2021-07-30 · Type 2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT06674135 · Life for a Child Program, Diabetes Australia
2022-06-01 – 2023-08-31 · Type I Diabetes
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 4 (1)
Type 2 Diabetes
NCT03819790 · LMC Diabetes & Endocrinology Ltd.
2018-10-02 – 2019-11-19 · Diabetes Mellitus, Type 2
What this study did

Competitive landscape

This mechanism is crowded: 12 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Type 1 Diabetes: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Insulin Glargine (Basaglar): this drugApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
AfrezzaApprovedPeptideInsulinPartial signal
NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed
NCT01445951: Change in HbA1c from baseline to week 24 (LS mean): Technosphere Insulin (Gen2 inhaler) plus basal insulin -0.21% vs insulin aspart plus basal insulin -0.40%; difference 0.19% (95% CI 0.02 to 0.36), inside the pre-specified non-inferiority margin of 0.4% (CT.gov posted analysis).
Insulin Aspart (NovoLog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (Fiasp)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Degludec (Tresiba)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Detemir (Levemir)
ApprovedUS marketing discontinued
PeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Lantus)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glargine (Toujeo)ApprovedPeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
Insulin Glulisine (Apidra)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin HumanApproved—Insulinnot yet gradedNo reviewed efficacy summary in this indication
Insulin Lispro (Humalog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Lispro (Lyumjev)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin NPH (Humulin N)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Pramlintide (Symlin)
ApprovedUS marketing discontinued
PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
CadisegliatinPhase 3Small moleculeGlucokinasenot yet gradedNo reviewed efficacy summary in this indication
Sotagliflozin (Inpefa)Phase 3Small moleculeSGLT1/2 (dual)not yet gradedNo reviewed efficacy summary in this indication
ZimislecelPhase 3Cell therapyPancreatic islet cells (VX-880 is a stem cell-derived therapy, not a small molecule drug), Pancreatic islet cell replacementnot yet gradedNo reviewed efficacy summary in this indication
IcovamenibPhase 2Small moleculeMeninnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.